Through ViiV Healthcare (majority owned by GSK), the world's only company 100% focused on HIV, we have been at the forefront of shifting the treatment paradigm for HIV. We have …

We are leaders in HIV, focused on ending the global epidemic. We have an industry-leading pipeline, driven by patient insights. Our global specialist HIV company, ViiV Healthcare, is fully …

Mar 12, 2025 · GSK plc (LSE/NYSE: GSK) announced that ViiV Healthcare, the global specialist HIV company majority owned by GSK, with Pfizer and Shionogi as shareholders, today …

Mar 12, 2025 · GSK’s ViiV Healthcare has shared clinical data on three potential long-acting HIV treatments, providing a look at how its plans to create a six-month regimen are shaping up.

Mar 9, 2025 · ViiV Healthcare is a global specialist HIV company established in November 2009 by GSK (LSE: GSK) and Pfizer (NYSE: PFE) dedicated to delivering advances in treatment …

Mar 12, 2025 · About ViiV Healthcare ViiV Healthcare is a global specialist HIV company established in November 2009 by GSK (LSE: GSK) and Pfizer (NYSE: PFE) dedicated to …

London, 12 March 2025 – ViiV Healthcare, the global specialist HIV company majority owned by GSK, with Pfizer and Shionogi as shareholders, today announced new data from two …

Feb 21, 2024 · British pharma giant GSK on Wednesday announced promising results for a long-acting injectable HIV therapy, offering a hopeful alternative for people who take daily pills to …

ected by HIV. For more information on the company, its management, portfolio, pipeline, and commitment, please visit viivheal

Sep 28, 2023 · GSK projects its HIV products will reach £7 billion pounds sterling ($8.5 billion) in sales by 2026, Deborah Waterhouse, CEO of GSK’s specialist HIV company ViiV Healthcare, …